Tweet
Vaccination against highly pathogenic avian influenza H5N1 virus in zoos using an adjuvanted inactivated H5N2 vaccine
Joost Philippa Corresponding Author Contact Information, E-mail The Corresponding Author, Chantal Baas, Walter Beyer, Theo Bestebroer, Ron Fouchier, Derek Smith, c, Willem Schaftenaar and Ab Osterhaus
Institute of Virology, Erasmus MC, P.O. Box 2040, 3000 CA, Rotterdam, The Netherlands
Rotterdam Zoo, P.O. Box 532, 3000 AM, Rotterdam, The Netherlands
Department of Zoology, University of Cambridge, Downing Street, Cambridge CB2 3EJ, UK
Received 28 November 2006; revised 23 January 2007; accepted 30 January 2007. Available online 26 February 2007.
Abstract
Highly pathogenic avian influenza (HPAI) H5N1 virus infections have recently caused unprecedented morbidity and mortality in a wide range of avian species. European Commission directive 2005/744/EC allowed vaccination in zoos under strict conditions, while reducing confinement measures. Vaccination with a commercial H5N2 vaccine with vaccine doses adapted to mean body weight per species was safe, and proved immunogenic throughout the range of species tested, with some variations between and within taxonomic orders. After booster vaccination the overall homologous geometric mean titre (GMT) to the vaccine strain, measured in 334 birds, was 190 (95% CI: 152?236), and 80.5% of vaccinated birds developed a titre of ≥40. Titres to the HPAI H5N1 virus followed a similar trend, but were lower (GMT: 61 (95% CI: 49?76); 61% ≥ 40). The breadth of the immune response was further demonstrated by measuring antibody titres against prototype strains of four antigenic clades of currently circulating H5N1 viruses. These data indicate that vaccination should be regarded as a beneficial component of the preventive measures (including increased bio-security and monitoring) that can be undertaken in zoos to prevent an outbreak of and decrease environmental contamination by HPAI H5N1 virus, while alleviating confinement measures.
Keywords: Avian influenza; H5N1; Vaccination; Zoo; Clade
Joost Philippa Corresponding Author Contact Information, E-mail The Corresponding Author, Chantal Baas, Walter Beyer, Theo Bestebroer, Ron Fouchier, Derek Smith, c, Willem Schaftenaar and Ab Osterhaus
Institute of Virology, Erasmus MC, P.O. Box 2040, 3000 CA, Rotterdam, The Netherlands
Rotterdam Zoo, P.O. Box 532, 3000 AM, Rotterdam, The Netherlands
Department of Zoology, University of Cambridge, Downing Street, Cambridge CB2 3EJ, UK
Received 28 November 2006; revised 23 January 2007; accepted 30 January 2007. Available online 26 February 2007.
Abstract
Highly pathogenic avian influenza (HPAI) H5N1 virus infections have recently caused unprecedented morbidity and mortality in a wide range of avian species. European Commission directive 2005/744/EC allowed vaccination in zoos under strict conditions, while reducing confinement measures. Vaccination with a commercial H5N2 vaccine with vaccine doses adapted to mean body weight per species was safe, and proved immunogenic throughout the range of species tested, with some variations between and within taxonomic orders. After booster vaccination the overall homologous geometric mean titre (GMT) to the vaccine strain, measured in 334 birds, was 190 (95% CI: 152?236), and 80.5% of vaccinated birds developed a titre of ≥40. Titres to the HPAI H5N1 virus followed a similar trend, but were lower (GMT: 61 (95% CI: 49?76); 61% ≥ 40). The breadth of the immune response was further demonstrated by measuring antibody titres against prototype strains of four antigenic clades of currently circulating H5N1 viruses. These data indicate that vaccination should be regarded as a beneficial component of the preventive measures (including increased bio-security and monitoring) that can be undertaken in zoos to prevent an outbreak of and decrease environmental contamination by HPAI H5N1 virus, while alleviating confinement measures.
Keywords: Avian influenza; H5N1; Vaccination; Zoo; Clade